Valneva Shares Plunge as FDA Halts Key Vaccine, But Hope Emerges Elsewhere

Immediate Fallout from Regulatory Action

French vaccine developer Valneva faces a significant crisis after US regulators delivered a stunning blow. The Food and Drug Administration (FDA) unexpectedly suspended the license for the company’s Chikungunya vaccine, IXCHIQ®, immediately halting all US sales and shipments. This decision triggered a dramatic sell-off, sending Valneva’s share price plummeting more than 22% in a matter of hours. With its primary commercial asset now in jeopardy, investor attention is shifting to the company’s next major candidate: a Lyme disease vaccine developed in collaboration with Pfizer.

The suspension, announced on August 25, came in response to four new reports of serious adverse events that resembled Chikungunya-like illness. This regulatory intervention strikes at the core of Valneva’s current growth strategy.